OSA Atomoxetine plus oxybutynin demonstrated efficacy in improving upper airway collapsibility, increasing breathing stability, and reducing the threshold for arousal in obstructive sleep apnea.

Clinical trial data indicate that atomoxetine is safe and well tolerated for the treatment of ADHD; however, safety data about long-term use (greater than one year) are unavailable. Adverse events ...

Atomoxetine is a potent central norepinephrine uptake inhibitor, currently marketed for treatment of attention-deficit/hyperactivity disorder (ADHD). With the ...

Please provide your email address to receive an email when new articles are posted on . “These findings suggest that a pharmacologic approach may eventually become an option for selected patients with ...

June 19, 2008 — In a large, placebo-controlled, head-to-head, 6-week trial, the response rate for osmotic-release oral system (OROS) methylphenidate (Concerta, McNeil Consumer & Specialty ...

Review the side-effects of Atomoxetine as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Atomoxetine (Attentrol (25 mg)) is a selective norepinephrine reuptake inhibitor (SNRI), prescribed for Attention deficit hyperactivity disorder (ADHD). It increases the level of norepinephrine in the ...

(HealthDay)—A considerable proportion of patients receiving atomoxetine (ATX), especially those receiving ATX monotherapy, do not reach the recommended dose of 80 mg/day (ATX ≥80), according to a ...

Please provide your email address to receive an email when new articles are posted on . Apnea-hypopnea index dropped by 42% with receipt of 1-week pimavanserin plus atomoxetine vs. placebo. Larger ...

NAPERVILLE, Ill., April 22, 2021 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and ...

Reason for posting: As a nonstimulant, atomoxetine is a popular new treatment for attention-deficit hyperactivity disorder (ADHD). However, the US Food and Drug Administration and Health Canada ...

Liège, Belgium – 24 October 2023 – 7AM CET – Non-regulated information - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs ...